- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic severe atopic dermatitis
- Meeting Date: July 2026
Dupilumab – July 2026
- Injection 200 mg in 1.14 mL single dose pre-filled syringe
- Injection 200 mg in 1.14 mL single dose pre-filled pen
- Injection 300 mg in 2 mL single dose pre-filled syringe
- Injection 300 mg in 2 mL single dose pre-filled pen
Public Summary Documents
Last updated
13 November 2026
